Tracers / [203Pb]eSOMA-01
[203Pb]eSOMA-01
- Radionuclide
- Pb-203
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Octreotate-based somatostatin analogue peptide (SSTR2-targeting)
- Target / mechanism
- Somatostatin receptor subtype 2 (SSTR2) PMID 37513897
- Clinical application
- Neuroendocrine tumors (NETs) PMID 37513897
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | ≥96% | ≥95% | eSOMA-01 | 37513897 2023 Pharmaceuticals (Basel) [203Pb]PbCl2 (40 MBq) in 0.5 M HCl ... was added to a mixture of DOTAM-TATE or eSOMA-(01-03) (1 nmol), ascorbic acid/gentisic acid (10 μL, 50 mM), sodium acetate (30 μL, 2.5 M), and H2O (final volume of 140 μL). The mixture was incubated for 20 min at rt. — All labeled compounds were obtained with a RCY ≥ 96% and a RCP ≥ 95%. |
Need this precursor?We can point you to suppliers for [203Pb]eSOMA-01, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37513897. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.